UY36077A - Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen - Google Patents

Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen

Info

Publication number
UY36077A
UY36077A UY0001036077A UY36077A UY36077A UY 36077 A UY36077 A UY 36077A UY 0001036077 A UY0001036077 A UY 0001036077A UY 36077 A UY36077 A UY 36077A UY 36077 A UY36077 A UY 36077A
Authority
UY
Uruguay
Prior art keywords
pteridin
ona
modulators
derivatives
amino
Prior art date
Application number
UY0001036077A
Other languages
English (en)
Inventor
Bakonyi Johanna
Steven Richard Brunette
Collin Delphine
Robert Owen Hughes
Li Xiang
Liang Shuang
Wu Lifen
Sibley Robert
Michael Robert Turner
Zhang Qiang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY36077A publication Critical patent/UY36077A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención comprende compuestos de la fórmula (I) en donde las variables se definen en la presente que son apropiadas para la modulación de RORy y el tratamiento de enfermedades relacionadas con la modulación de RORy. La presente invención también comprende procesos de preparación de compuestos de la fórmula (I) y preparaciones farmacéuticas que los contienen.
UY0001036077A 2014-04-14 2015-04-13 Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen UY36077A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14

Publications (1)

Publication Number Publication Date
UY36077A true UY36077A (es) 2015-10-30

Family

ID=52998264

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036077A UY36077A (es) 2014-04-14 2015-04-13 Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen

Country Status (36)

Country Link
US (5) US9242989B2 (es)
EP (2) EP3131902B1 (es)
JP (2) JP6282759B2 (es)
KR (2) KR102410076B1 (es)
CN (3) CN107266450B (es)
AP (1) AP2016009403A0 (es)
AR (2) AR100058A1 (es)
AU (2) AU2015247983B2 (es)
BR (2) BR112016021962A2 (es)
CA (1) CA2944787C (es)
CL (1) CL2016002421A1 (es)
CY (1) CY1122012T1 (es)
DK (1) DK3131902T3 (es)
EA (2) EA035063B1 (es)
ES (1) ES2744299T3 (es)
HK (2) HK1244800A1 (es)
HR (1) HRP20191579T1 (es)
HU (1) HUE045847T2 (es)
IL (2) IL247419B (es)
LT (1) LT3131902T (es)
MA (1) MA46373A (es)
ME (1) ME03513B (es)
MX (1) MX370780B (es)
MY (1) MY182834A (es)
NZ (1) NZ723530A (es)
PE (2) PE20211002A1 (es)
PH (2) PH12016502019B1 (es)
PL (1) PL3131902T3 (es)
PT (1) PT3131902T (es)
RS (1) RS59170B1 (es)
SG (1) SG11201608537SA (es)
SI (1) SI3131902T1 (es)
TW (2) TWI655192B (es)
UA (2) UA120094C2 (es)
UY (1) UY36077A (es)
WO (1) WO2015160654A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160654A1 (en) * 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
EP3845526A1 (en) 2015-05-15 2021-07-07 Aurigene Discovery Technologies Limited Method for the preparation of tetrahydroquinolinone compounds having ror-gamma modulating activity
JP6778259B2 (ja) 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
WO2017127375A1 (en) * 2016-01-20 2017-07-27 Boehringer Ingelheim International Gmbh Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
US10196350B2 (en) 2016-12-05 2019-02-05 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
ES2949366T3 (es) 2018-05-03 2023-09-28 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivados de bencimidazol como moduladores del receptor huérfano gamma relacionado con retinoides (rory) y usos farmacéuticos de los mismos
JP2022504780A (ja) 2018-10-18 2022-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 光学活性１－シクロプロピルアルキル－１－アミンのスケーラブルな合成
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
EP4053109A4 (en) 2019-10-31 2022-12-21 Jiangsu Hengrui Medicine Co., Ltd. ACID ADDITION SALT BY RORy REGLER
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
WO2023216910A1 (zh) * 2022-05-07 2023-11-16 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN116178279A (zh) * 2023-03-15 2023-05-30 上海药坦药物研究开发有限公司 一种5-溴-4-环丙基-6-甲氧基嘧啶及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
CN102227425A (zh) 2008-09-26 2011-10-26 贝林格尔·英格海姆国际有限公司 作为ccr1受体拮抗剂的氮杂吲唑化合物
RS53130B (en) 2009-10-21 2014-06-30 Boehringer Ingelheim International Gmbh INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
WO2012167046A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2013170671A1 (zh) * 2012-05-14 2013-11-21 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
WO2015160654A1 (en) * 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
JP6778259B2 (ja) * 2015-10-01 2020-10-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしてのプテリジン誘導体
WO2017127375A1 (en) * 2016-01-20 2017-07-27 Boehringer Ingelheim International Gmbh Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Also Published As

Publication number Publication date
HK1244801A1 (zh) 2018-08-17
EP3418280A1 (en) 2018-12-26
CA2944787C (en) 2023-03-14
MA46373A (fr) 2019-08-07
PE20161572A1 (es) 2017-02-01
AU2015247983B2 (en) 2019-05-16
AU2015247983A1 (en) 2016-09-08
MY182834A (en) 2021-02-05
CN107266454B (zh) 2019-08-09
CN107266450A (zh) 2017-10-20
EA201890329A1 (ru) 2018-07-31
KR20200040917A (ko) 2020-04-20
TWI655192B (zh) 2019-04-01
ME03513B (me) 2020-04-20
US20180022749A1 (en) 2018-01-25
EP3131902B1 (en) 2019-06-12
EA201691978A1 (ru) 2017-02-28
HK1244800A1 (zh) 2018-08-17
NZ723530A (en) 2023-05-26
JP2018065874A (ja) 2018-04-26
KR20160142396A (ko) 2016-12-12
SI3131902T1 (sl) 2019-10-30
TW201625622A (zh) 2016-07-16
CA2944787A1 (en) 2015-10-22
EP3418280B1 (en) 2023-07-12
DK3131902T3 (da) 2019-09-02
US9598415B2 (en) 2017-03-21
JP6463855B2 (ja) 2019-02-06
KR102410069B1 (ko) 2022-06-20
MX2016013342A (es) 2017-01-26
AP2016009403A0 (en) 2016-08-31
UA121255C2 (uk) 2020-04-27
LT3131902T (lt) 2019-09-25
US20170008894A1 (en) 2017-01-12
AU2019203027B2 (en) 2020-07-09
BR112016021962A2 (pt) 2023-01-20
AU2019203027A1 (en) 2019-05-23
EA031351B1 (ru) 2018-12-28
US20160075706A1 (en) 2016-03-17
JP6282759B2 (ja) 2018-02-21
TWI652268B (zh) 2019-03-01
AR119454A2 (es) 2021-12-22
CL2016002421A1 (es) 2017-03-24
PT3131902T (pt) 2019-09-17
KR102410076B1 (ko) 2022-06-22
UA120094C2 (uk) 2019-10-10
AR100058A1 (es) 2016-09-07
IL263878B (en) 2019-11-28
WO2015160654A1 (en) 2015-10-22
MX370780B (es) 2020-01-03
EP3131902A1 (en) 2017-02-22
CN106132965A (zh) 2016-11-16
CN106132965B (zh) 2020-02-07
CN107266454A (zh) 2017-10-20
HUE045847T2 (hu) 2020-01-28
PE20211002A1 (es) 2021-06-01
TW201841915A (zh) 2018-12-01
RS59170B1 (sr) 2019-10-31
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
ES2744299T3 (es) 2020-02-24
CN107266450B (zh) 2020-07-24
US20190002465A1 (en) 2019-01-03
EA035063B1 (ru) 2020-04-23
PH12016502019A1 (en) 2017-01-09
PH12020500252A1 (en) 2021-07-26
BR122020020657B1 (pt) 2022-12-20
JP2017511357A (ja) 2017-04-20
SG11201608537SA (en) 2016-11-29
CY1122012T1 (el) 2020-10-14
PH12016502019B1 (en) 2017-01-09
US9242989B2 (en) 2016-01-26
PL3131902T3 (pl) 2019-11-29
BR112016021962B1 (pt) 2022-12-13
HRP20191579T1 (hr) 2019-11-29
US20150291607A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP19083923A (es) Inhibidores pirazólicos de magl
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
DOP2019000122A (es) Inhibidores de magl
ECSP19035377A (es) Inhibidores de magl
CL2019001336A1 (es) Inhibidores de la magl.
CL2020000085A1 (es) Moduladores de nlrp3.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2019001406A1 (es) Moduladores de ror gamma (rory).
MX2020004871A (es) Derivados de acido cafeico y sus usos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230224